{
  "annotationGroups" : [ {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166248401",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166248401",
    "name" : "521 CC",
    "genePhenotypes" : [ "SLCO1B1:Decreased function/Decreased function" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182843",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182843",
      "name" : "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
      "version" : 8
    },
    "implications" : {
      "id" : 1451492915,
      "html" : "<p>The risk of myopathy may be increased. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase the atorvastatin plasma concentration.</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451492916,
      "html" : "<p>Patient with the <em>SLCO1B1</em> 521 CC genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451492917,
      "html" : "<ul>\n<li>Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Choose an alternative.\nDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.</li>\n<li>If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n<ul>\n<li>Patient has NO additional significant risk factors for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602496",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602496,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Possibly",
      "termId" : "rxChange:1448602496",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166248402",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166248402",
    "name" : "521 CT",
    "genePhenotypes" : [ "SLCO1B1:Decreased function/Normal function" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182843",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182843",
      "name" : "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
      "version" : 8
    },
    "implications" : {
      "id" : 1451492868,
      "html" : "<p>The risk of myopathy can be elevated. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase atorvastatin plasma concentrations.</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451492869,
      "html" : "<p>Patient with the <em>SLCO1B1</em> 521 CT genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451492870,
      "html" : "<ul>\n<li>Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Choose an alternative.\nRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.</li>\n<li>If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n<ul>\n<li>Patient has NO additional significant risk factors for statin-induced myopathy:</li>\n</ul>\n<ol>\n<li>Advise the patient to contact their doctor in the event of muscle symptoms.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602496",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602496,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Possibly",
      "termId" : "rxChange:1448602496",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166248421",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166248421",
    "name" : "521 TT",
    "genePhenotypes" : [ "SLCO1B1:Normal function/Normal function" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182843",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182843",
      "name" : "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
      "version" : 8
    },
    "implications" : {
      "id" : 1451492912,
      "html" : "<p>The guideline does not provide a description of the impact of the <em>SLCO1B1</em> 521 TT genotype on atorvastatin.</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451492913,
      "html" : "<p>Patient with the <em>SLCO1B1</em> 521 TT genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451492914,
      "html" : "<p>The guideline does not provide a recommendation for atorvastatin in patients with the <em>SLCO1B1</em> 521 TT genotype</p>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  } ],
  "citations" : [ ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182843",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166182843",
    "name" : "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "guidelineGenes" : [ {
      "id" : 1451492860,
      "alleles" : [ {
        "id" : 1451492881,
        "_label" : "c.521 C",
        "allele" : "c.521 C",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "version" : 0
      }, {
        "id" : 1451492863,
        "_label" : "c.521 T",
        "allele" : "c.521 T",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558335,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Normal function",
          "termId" : "haplotypeTags:1445558335",
          "version" : 1
        },
        "version" : 0
      } ],
      "gene" : {
        "@id" : "https://pharmgkb.org/gene/PA134865839",
        "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
        "objCls" : "Gene",
        "id" : "PA134865839",
        "symbol" : "SLCO1B1",
        "name" : "solute carrier organic anion transporter family member 1B1",
        "alleleFile" : "SLCO1B1_allele_definition_table.xlsx",
        "altNames" : {
          "synonym" : [ "solute carrier organic anion transporter family, member 1B1" ],
          "symbol" : [ "LST-1", "OATP-C", "OATP1B1", "SLC21A6" ]
        },
        "buildVersion" : "GRCh38",
        "cbStart" : "p12.2",
        "cbStop" : "p12.1",
        "chr" : {
          "@id" : "https://pharmgkb.org/chromosome/PA508",
          "@context" : "https://api.pharmgkb.org/jsonld/chromosome.jsonld",
          "objCls" : "Chromosome",
          "id" : "PA508",
          "name" : "chr12",
          "version" : 3
        },
        "chrStartPosB37" : 21284128,
        "chrStartPosB38" : 21131194,
        "chrStopPosB37" : 21392730,
        "chrStopPosB38" : 21239796,
        "cpicGene" : true,
        "crossReferences" : [ {
          "@id" : "https://pharmgkb.org/crossReference/alfred/LO013242M",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608076670,
          "resource" : "ALFRED",
          "resourceId" : "LO013242M",
          "_url" : "http://alfred.med.yale.edu/alfred/recordinfop.asp?UNID=LO013242M",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/ctd/10599",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 553239425,
          "resource" : "Comparative Toxicogenomics Database",
          "resourceId" : "10599",
          "_url" : "http://ctdbase.org/detail.go?type=gene&acc=10599",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/ensembl/ENSG00000134538",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 132269853,
          "resource" : "Ensembl",
          "resourceId" : "ENSG00000134538",
          "_url" : "http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134538",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/genAtlas/SLCO1B1",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 123067002,
          "resource" : "GenAtlas",
          "resourceId" : "SLCO1B1",
          "_url" : "http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=SLCO1B1",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/geneCard/SLCO1B1",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 123067003,
          "resource" : "GeneCard",
          "resourceId" : "SLCO1B1",
          "_url" : "http://www.genecards.org/cgi-bin/carddisp.pl?gene=SLCO1B1",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0005215",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34950,
          "resource" : "GO",
          "resourceId" : "GO:0005215",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0005215",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0005624",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34644,
          "resource" : "GO",
          "resourceId" : "GO:0005624",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0005624",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0005887",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34662,
          "resource" : "GO",
          "resourceId" : "GO:0005887",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0005887",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0006811",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 35126,
          "resource" : "GO",
          "resourceId" : "GO:0006811",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0006811",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0015347",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 36013,
          "resource" : "GO",
          "resourceId" : "GO:0015347",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0015347",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0015711",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 35283,
          "resource" : "GO",
          "resourceId" : "GO:0015711",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0015711",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0016020",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34795,
          "resource" : "GO",
          "resourceId" : "GO:0016020",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0016020",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/hgnc/HGNC:10959",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608076669,
          "resource" : "HGNC",
          "resourceId" : "HGNC:10959",
          "_url" : "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC%3A10959",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/HumanCycGene/HS05882",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608076672,
          "resource" : "HumanCyc Gene",
          "resourceId" : "HS05882",
          "_url" : "http://biocyc.org/HUMAN/NEW-IMAGE?object=HS05882",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/modBase/Q9Y6L6",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 560876433,
          "resource" : "ModBase",
          "resourceId" : "Q9Y6L6",
          "_url" : "http://salilab.org/modbase/search?modelflag=longest&databaseID=Q9Y6L6",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/mutDb/SLCO1B1",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 123067005,
          "resource" : "MutDB",
          "resourceId" : "SLCO1B1",
          "_url" : "http://www.mutdb.org/genes/search?_method=POST&data%5BSearch%5D%5Bidentifier%5D=SLCO1B1",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/entrezGene/10599",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 9284,
          "resource" : "NCBI Gene",
          "resourceId" : "10599",
          "_url" : "https://www.ncbi.nlm.nih.gov/gene/10599",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/omim/604843",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 7200,
          "resource" : "OMIM",
          "resourceId" : "604843",
          "_url" : "http://omim.org/entry/604843",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/pharmVarGene/SLCO1B1",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 1451669412,
          "resource" : "PharmVar Gene",
          "resourceId" : "SLCO1B1",
          "_url" : "https://www.pharmvar.org/gene/SLCO1B1",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqDna/NG_011745.1",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 1451151134,
          "name" : "NG_011745.1",
          "resource" : "RefSeq DNA",
          "resourceId" : "NG_011745.1",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NG_011745.1",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqProtein/NP_006437",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 42861,
          "resource" : "RefSeq Protein",
          "resourceId" : "NP_006437",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NP_006437",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqRna/NM_006446",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 51961,
          "resource" : "RefSeq RNA",
          "resourceId" : "NM_006446",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NM_006446",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/ucscGenomeBrowser/NM_006446",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 120845,
          "resource" : "UCSC Genome Browser",
          "resourceId" : "NM_006446",
          "_url" : "http://genome.ucsc.edu/cgi-bin/hgTracks?Submit=Submit&position=NM_006446",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/uniProtKb/Q05CV5",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608076671,
          "name" : "Q05CV5_HUMAN",
          "resource" : "UniProtKB",
          "resourceId" : "Q05CV5",
          "_url" : "http://www.uniprot.org/uniprot/Q05CV5",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/uniProtKb/Q9Y6L6",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 77698353,
          "name" : "SO1B1_HUMAN",
          "resource" : "UniProtKB",
          "resourceId" : "Q9Y6L6",
          "_url" : "http://www.uniprot.org/uniprot/Q9Y6L6",
          "version" : 1
        } ],
        "hasNonStandardHaplotypes" : false,
        "hideHaplotypes" : false,
        "pharmVarGene" : true,
        "strand" : "plus",
        "terms" : [ {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005215","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560499603,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005215","resource":"Gene Ontology","term":"transporter activity","termId":"GO:0005215"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005624","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560495464,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005624","resource":"Gene Ontology","term":"membrane fraction","termId":"GO:0005624"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005886","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560500224,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005886","resource":"Gene Ontology","term":"plasma membrane","termId":"GO:0005886"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005887","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560500225,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005887","resource":"Gene Ontology","term":"integral to plasma membrane","termId":"GO:0005887"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0006811","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560501464,"_url":"http://amigo.geneontology.org/amigo/term/GO:0006811","resource":"Gene Ontology","term":"ion transport","termId":"GO:0006811"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0015347","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560506053,"_url":"http://amigo.geneontology.org/amigo/term/GO:0015347","resource":"Gene Ontology","term":"sodium-independent organic anion transmembrane transporter activity","termId":"GO:0015347"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0015711","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560506370,"_url":"http://amigo.geneontology.org/amigo/term/GO:0015711","resource":"Gene Ontology","term":"organic anion transport","termId":"GO:0015711"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0016323","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560506899,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016323","resource":"Gene Ontology","term":"basolateral plasma membrane","termId":"GO:0016323"} ],
        "version" : 49
      },
      "version" : 0
    } ],
    "hasTestingGuidance" : true,
    "history" : [ {
      "id" : 1450415243,
      "date" : "2019-05-27T00:00:00-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450820770,
      "date" : "2019-10-06T21:39:33.327-07:00",
      "description" : "No changes based on August 2019 guideline",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450962620,
      "date" : "2020-02-10T09:46:49.659-08:00",
      "description" : "Fixed links to 2018 guideline pdfs.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451257940,
      "date" : "2020-08-31T17:59:15.027-07:00",
      "description" : "updated wording to reflect August 2020 update",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451471600,
      "date" : "2021-07-16T13:53:38.363-07:00",
      "description" : "fixed typo for 521 T>C in the table",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451492885,
      "date" : "2021-09-08T00:00:00-07:00",
      "description" : "Added extended dosing guideline",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451704170,
      "date" : "2022-03-03T16:33:21.337-08:00",
      "description" : "Annotation current with May 2021 DPWG Guideline release",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1451706180,
      "date" : "2022-03-07T14:33:51.811-08:00",
      "description" : "Added information about preemptive genotyping",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451732810,
      "date" : "2022-03-28T09:57:35.073-07:00",
      "description" : "Annotation current with February 2022 DPWG guideline release",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1451733288,
      "date" : "2022-03-28T14:32:45.557-07:00",
      "description" : "Updated link to testing guidance page",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451741444,
      "date" : "2022-04-05T11:10:05.219-07:00",
      "description" : "Added testing guidance tag",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}],"objCls":"Literature"}, {"@id":"https://pharmgkb.org/literature/15113882","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15113882,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2020","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2020.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2020.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451257580,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2020.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2020.pdf"}],"objCls":"Literature"}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}],"objCls":"Literature"} ],
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/variant/PA166154579",
      "@context" : "https://api.pharmgkb.org/jsonld/variant.jsonld",
      "objCls" : "Variant",
      "id" : "PA166154579",
      "symbol" : "rs4149056",
      "name" : "rs4149056",
      "version" : 5
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA448500",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448500",
      "name" : "atorvastatin",
      "version" : 21
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA134865839",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA134865839",
      "symbol" : "SLCO1B1",
      "name" : "solute carrier organic anion transporter family member 1B1",
      "version" : 49
    } ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1450415241,
      "html" : "<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.</p>\n",
      "version" : 0
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1450415242,
      "html" : "<h3 id=\"august-2020-guideline-update\">August 2020 Guideline update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atorvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, they advise contacting their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from <a download=\"DPWG_August_2020.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf\">Dutch guidelines August 2020 update</a></em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><em>SLCO1B1</em> 521 CC</td>\n<td>atorvastatin</td>\n<td>The risk of myopathy may be increased. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase the atorvastatin plasma concentration.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative.<br/>Do not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n<tr>\n<td><em>SLCO1B1</em> 521 TC</td>\n<td>atorvastatin</td>\n<td>The risk of myopathy can be elevated. The gene variation may lead to reduced atorvastatin transport to the liver, which may increase atorvastatin plasma concentrations.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative.<br/>Rosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n</tbody>\n</table>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0004058.PDF\" target=\"_blank\">DPWG risk analysis document</a> for atorvastatin and SLCO1B1:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers genotyping before starting atorvastatin to be potentially beneficial for the prevention of side effects. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the KNMP Pharmacogenetics Working Group recommends adhering to the genedrug guideline.</p>\n</blockquote>\n<p><a href=\"/page/testingGuidance\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0004058.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atorvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, they advise contacting their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a></em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>521 CC</td>\n<td>atorvastatin</td>\n<td>The genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n<tr>\n<td>521 TC</td>\n<td>atorvastatin</td>\n<td>The genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.</td>\n<td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0004058.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n",
      "version" : 5
    },
    "userId" : "lgong",
    "version" : 8
  }
}